180 related articles for article (PubMed ID: 11511511)
1. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1.
Vrtala S; Hirtenlehner K; Susani M; Akdis M; Kussebi F; Akdis CA; Blaser K; Hufnagl P; Binder BR; Politou A; Pastore A; Vangelista L; Sperr WR; Semper H; Valent P; Ebner C; Kraft D; Valenta R
FASEB J; 2001 Sep; 15(11):2045-7. PubMed ID: 11511511
[TBL] [Abstract][Full Text] [Related]
2. T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies.
Vrtala S; Akdis CA; Budak F; Akdis M; Blaser K; Kraft D; Valenta R
J Immunol; 2000 Dec; 165(11):6653-9. PubMed ID: 11086111
[TBL] [Abstract][Full Text] [Related]
3. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1.
Gafvelin G; Thunberg S; Kronqvist M; Grönlund H; Grönneberg R; Troye-Blomberg M; Akdis M; Fiebig H; Purohit A; Horak F; Reisinger J; Niederberger V; Akdis CA; Cromwell O; Pauli G; Valenta R; van Hage M
Int Arch Allergy Immunol; 2005 Sep; 138(1):59-66. PubMed ID: 16103688
[TBL] [Abstract][Full Text] [Related]
4. Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season.
van Hage-Hamsten M; Kronqvist M; Zetterström O; Johansson E; Niederberger V; Vrtala S; Grönlund H; Grönneberg R; Valenta R
J Allergy Clin Immunol; 1999 Nov; 104(5):969-77. PubMed ID: 10550741
[TBL] [Abstract][Full Text] [Related]
5. Prevention of allergen-specific IgE production and suppression of an established Th2-type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch-pollen allergen.
Hochreiter R; Stepanoska T; Ferreira F; Valenta R; Vrtala S; Thalhamer J; Hartl A
Eur J Immunol; 2003 Jun; 33(6):1667-76. PubMed ID: 12778485
[TBL] [Abstract][Full Text] [Related]
6. Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1.
Mahler V; Vrtala S; Kuss O; Diepgen TL; Suck R; Cromwell O; Fiebig H; Hartl A; Thalhamer J; Schuler G; Kraft D; Valenta R
Clin Exp Allergy; 2004 Jan; 34(1):115-22. PubMed ID: 14720271
[TBL] [Abstract][Full Text] [Related]
7. Differential T-cell responses and allergen uptake after exposure of dendritic cells to the birch pollen allergens Bet v 1.0101, Bet v 1.0401 and Bet v 1.1001.
Smole U; Balazs N; Hoffmann-Sommergruber K; Radauer C; Hafner C; Wallner M; Ferreira F; Grössinger R; de Jong EC; Wagner S; Breiteneder H
Immunobiology; 2010 Nov; 215(11):903-9. PubMed ID: 20005001
[TBL] [Abstract][Full Text] [Related]
8. Characterization of wild-type recombinant Bet v 1a as a candidate vaccine against birch pollen allergy.
Batard T; Didierlaurent A; Chabre H; Mothes N; Bussières L; Bohle B; Couret MN; Ball T; Lemoine P; Focks Tejkl M; Chenal A; Clément G; Dupont F; Valent P; Krauth MT; André C; Valenta R; Moingeon P
Int Arch Allergy Immunol; 2005 Mar; 136(3):239-49. PubMed ID: 15722633
[TBL] [Abstract][Full Text] [Related]
9. Bet v 1, the major birch pollen allergen, initiates sensitization to Api g 1, the major allergen in celery: evidence at the T cell level.
Bohle B; Radakovics A; Jahn-Schmid B; Hoffmann-Sommergruber K; Fischer GF; Ebner C
Eur J Immunol; 2003 Dec; 33(12):3303-10. PubMed ID: 14635038
[TBL] [Abstract][Full Text] [Related]
10. Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a French population.
Pauli G; Purohit A; Oster JP; De Blay F; Vrtala S; Niederberger V; Kraft D; Valenta R
Clin Exp Allergy; 2000 Aug; 30(8):1076-84. PubMed ID: 10931114
[TBL] [Abstract][Full Text] [Related]
11. Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy.
Ferreira F; Hirtenlehner K; Jilek A; Godnik-Cvar J; Breiteneder H; Grimm R; Hoffmann-Sommergruber K; Scheiner O; Kraft D; Breitenbach M; Rheinberger HJ; Ebner C
J Exp Med; 1996 Feb; 183(2):599-609. PubMed ID: 8627171
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the T cell response to the major hazelnut allergen, Cor a 1.04: evidence for a relevant T cell epitope not cross-reactive with homologous pollen allergens.
Bohle B; Radakovics A; Lüttkopf D; Jahn-Schmid B; Vieths S; Ebner C
Clin Exp Allergy; 2005 Oct; 35(10):1392-9. PubMed ID: 16238801
[TBL] [Abstract][Full Text] [Related]
13.
Aglas L; Bethanis A; Chrusciel P; Stolz F; Gruen M; Jaakkola UM; Jongejan L; Yatkin E; Van Ree R
Front Immunol; 2020; 11():2118. PubMed ID: 33013894
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy.
Kahlert H; Suck R; Weber B; Nandy A; Wald M; Keller W; Cromwell O; Fiebig H
Int Arch Allergy Immunol; 2008; 145(3):193-206. PubMed ID: 17912007
[TBL] [Abstract][Full Text] [Related]
15. Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen bet v 1 and to recombinant bet v 1 wild type in skin chamber fluids collected from birch pollen-allergic patients.
Nopp A; Halldén G; Lundahl J; Johansson E; Vrtala S; Valenta R; Grönneberg R; Van Hage-Hamsten M
J Allergy Clin Immunol; 2000 Jul; 106(1 Pt 1):101-9. PubMed ID: 10887312
[TBL] [Abstract][Full Text] [Related]
16. Oral exposure to Mal d 1 affects the immune response in patients with birch pollen allergy.
Geroldinger-Simic M; Kinaciyan T; Nagl B; Baumgartner-Durchschlag U; Huber H; Ebner C; Lidholm J; Bartel D; Vieths S; Jahn-Schmid B; Bohle B
J Allergy Clin Immunol; 2013 Jan; 131(1):94-102. PubMed ID: 22921871
[TBL] [Abstract][Full Text] [Related]
17. Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination.
Vrtala S; Fohr M; Campana R; Baumgartner C; Valent P; Valenta R
Vaccine; 2011 Mar; 29(11):2140-8. PubMed ID: 21215346
[TBL] [Abstract][Full Text] [Related]
18. Mapping of conformational IgE epitopes with peptide-specific monoclonal antibodies reveals simultaneous binding of different IgE antibodies to a surface patch on the major birch pollen allergen, Bet v 1.
Gieras A; Cejka P; Blatt K; Focke-Tejkl M; Linhart B; Flicker S; Stoecklinger A; Marth K; Drescher A; Thalhamer J; Valent P; Majdic O; Valenta R
J Immunol; 2011 May; 186(9):5333-44. PubMed ID: 21451110
[TBL] [Abstract][Full Text] [Related]
19. Nonallergic individuals recognize the same T cell epitopes of Bet v 1, the major birch pollen allergen, as atopic patients.
Ebner C; Schenk S; Najafian N; Siemann U; Steiner R; Fischer GW; Hoffmann K; Szépfalusi Z; Scheiner O; Kraft D
J Immunol; 1995 Feb; 154(4):1932-40. PubMed ID: 7530747
[TBL] [Abstract][Full Text] [Related]
20. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation.
van Neerven RJ; Wikborg T; Lund G; Jacobsen B; Brinch-Nielsen A; Arnved J; Ipsen H
J Immunol; 1999 Sep; 163(5):2944-52. PubMed ID: 10453043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
